Longitudinal and multimodal auditing of tumor adaptation to CDK4/6 inhibitors in HR+ metastatic breast cancers
A. L. Creason, J. Egger, C. Watson, S. Sivagnanam, K. Chin, K. MacPherson, J.-R. Lin, Y.-A. Chen, B. E. Johnson, H. S. Feiler, D. Galipeau, N. E. Navin, E. Demir, Y. H. Chang, C. L. Corless, , J. Goecks
This study creates a multimodal tumor atlas to analyze how metastatic HR+ breast cancers adapt to CDK4/6 inhibitors, revealing mechanisms like mTORC1 activation and immune microenvironment changes.
bioRxiv · Sep 27, 2023 · PreprintCancer Biology